CN115475189A - Jade screen powder micro powder and preparation method and application thereof - Google Patents
Jade screen powder micro powder and preparation method and application thereof Download PDFInfo
- Publication number
- CN115475189A CN115475189A CN202211156884.0A CN202211156884A CN115475189A CN 115475189 A CN115475189 A CN 115475189A CN 202211156884 A CN202211156884 A CN 202211156884A CN 115475189 A CN115475189 A CN 115475189A
- Authority
- CN
- China
- Prior art keywords
- powder
- sieving
- jade screen
- raw materials
- micropowder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 84
- 239000010977 jade Substances 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 238000007873 sieving Methods 0.000 claims abstract description 21
- 239000002994 raw material Substances 0.000 claims abstract description 20
- 238000001035 drying Methods 0.000 claims abstract description 14
- 238000002156 mixing Methods 0.000 claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 238000005303 weighing Methods 0.000 claims abstract description 7
- 241000132012 Atractylodes Species 0.000 claims abstract description 6
- 235000006533 astragalus Nutrition 0.000 claims abstract description 6
- 241001180876 Saposhnikovia Species 0.000 claims abstract description 5
- 238000010298 pulverizing process Methods 0.000 claims abstract description 4
- 241000045403 Astragalus propinquus Species 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims description 31
- 239000002245 particle Substances 0.000 claims description 15
- 229930182470 glycoside Natural products 0.000 claims description 10
- -1 isoflavone glucoside Chemical class 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 150000002338 glycosides Chemical class 0.000 claims description 5
- FBMORZZOJSDNRQ-GLQYFDAESA-N Atractylenolide III Chemical compound C=C([C@@H]1C2)CCC[C@]1(C)C[C@@]1(O)C2=C(C)C(=O)O1 FBMORZZOJSDNRQ-GLQYFDAESA-N 0.000 claims description 4
- 229930182478 glucoside Natural products 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 3
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims description 3
- 235000008696 isoflavones Nutrition 0.000 claims description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 2
- FBMORZZOJSDNRQ-UHFFFAOYSA-N Demethoxy,B,HCl-Adriamycin Natural products C1C2C(=C)CCCC2(C)CC2(O)C1=C(C)C(=O)O2 FBMORZZOJSDNRQ-UHFFFAOYSA-N 0.000 claims description 2
- 206010061126 Escherichia infection Diseases 0.000 claims description 2
- 240000007594 Oryza sativa Species 0.000 claims description 2
- 235000007164 Oryza sativa Nutrition 0.000 claims description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 2
- OAXKIRPCKWQWOQ-UHFFFAOYSA-N atractylenolide III Natural products CC1=C2CC3C(CCCC3=C)CC2(O)OC1=O OAXKIRPCKWQWOQ-UHFFFAOYSA-N 0.000 claims description 2
- 208000020612 escherichia coli infection Diseases 0.000 claims description 2
- 238000007781 pre-processing Methods 0.000 claims description 2
- 235000009566 rice Nutrition 0.000 claims description 2
- 239000010981 turquoise Substances 0.000 claims description 2
- 235000019155 vitamin A Nutrition 0.000 claims description 2
- 239000011719 vitamin A Substances 0.000 claims description 2
- 229940045997 vitamin a Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 20
- 239000000463 material Substances 0.000 abstract description 12
- 230000000052 comparative effect Effects 0.000 description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 13
- 239000009571 yupingfeng Substances 0.000 description 13
- 238000000605 extraction Methods 0.000 description 10
- 210000000056 organ Anatomy 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000000341 volatile oil Substances 0.000 description 5
- 241001061264 Astragalus Species 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000006996 mental state Effects 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 210000004233 talus Anatomy 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000009636 Huang Qi Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- QVGFPTYGKPLXPK-OOBAEQHESA-N (2s)-4-methoxy-7-methyl-2-[2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl]-2,3-dihydrofuro[3,2-g]chromen-5-one Chemical compound CC([C@@H]1CC2=C(C=3C(=O)C=C(C)OC=3C=C2O1)OC)(C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QVGFPTYGKPLXPK-OOBAEQHESA-N 0.000 description 1
- 241000092665 Atractylodes macrocephala Species 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- ZZAJQOPSWWVMBI-UHFFFAOYSA-N Calycosin Natural products C1=C(O)C(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZZAJQOPSWWVMBI-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- HVTPIQKJZSQSLM-UHFFFAOYSA-N cimicidine Natural products C12=CC=C(OC)C(O)=C2N(C(=O)CC)C2C11CCN(CCC3)C41OC(=O)CC43CC2 HVTPIQKJZSQSLM-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a micropowder of jade screen powder and a preparation method and application thereof, comprising the following steps: s1, weighing raw materials: weighing the following raw materials in parts by weight: 2 parts of astragalus membranaceus, 2 parts of bighead atractylodes rhizome and 1 part of divaricate saposhnikovia root; s2, drying: mixing the raw materials in the step S1, and drying; s3, primary sieving: pulverizing the dried raw materials, and sieving for one time; s4, secondary sieving: and (4) secondarily crushing the raw materials after primary sieving, and secondarily sieving to obtain the jade screen powder micro powder. The jade screen powder prepared by the invention has the advantages of simple preparation method, few auxiliary materials, small side effect, safety and reliability, not only greatly improves the content of active ingredients and saves the cost of medicinal materials, but also has obvious curative effect on colibacillosis and can enhance the immunocompetence of mice to a certain extent.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicine dosage forms, in particular to jade screen powder micro powder and a preparation method and application thereof.
Background
Yupingfeng powder is a classic prescription for strengthening body resistance and consolidating constitution in the field of traditional Chinese medicine, has less medicinal ingredients and strict compatibility, only consists of three medicines of astragalus, bighead atractylodes rhizome and divaricate saposhnikovia root, has the effects of tonifying qi, consolidating exterior and arresting sweating, and is commonly used for treating exterior deficiency spontaneous perspiration and diseases easily infected by wind evil.
The common Yupingfeng powder preparations on the market at present comprise granules, oral liquid and dropping pills. The preparation process of various dosage forms is different, and the specific steps are as follows:
jade screen wind particle: placing radix Saposhnikoviae in a volatile oil extractor, extracting volatile oil, and collecting distilled water solution in another extractor. Decocting the residue, radix astragali and Atractylodis rhizoma in water for 1 hr for 3 times, mixing decoctions, and filtering. Mixing the filtrate and the water solution, standing for precipitation, and filtering. Concentrating the filtrate to obtain fluid extract, adding sucrose powder and dextrin, spray drying granulating machine, granulating, adding the volatile oil, mixing, and making into granule.
Yupingfeng oral liquid: extracting volatile oil from radix Saposhnikoviae, storing the distillate separately, mixing the residues with radix astragali and Atractylodis rhizoma, decocting for 2 times, mixing decoctions, filtering, concentrating, precipitating with ethanol, recovering ethanol, adding water, filtering, concentrating, adding sucrose to obtain syrup, adding volatile oil and distillate, stirring, and sterilizing.
Yupingfeng dripping pill: extracting volatile components from radix sileris by a steam distillation method, keeping the distillate in another container, mixing the dregs of a decoction with the astragalus and the white atractylodes rhizome, performing percolation extraction by 0-100% of ethanol or ethyl acetate, heating extraction or soaking extraction or decocting extraction by water, collecting an extracting solution, recovering a solvent, or mixing the extracting solution with the distillate, and concentrating the extracting solution into a thick extract; mixing the soft extract or volatile components, adding into melted dripping pill matrix, mixing, and making into dripping pill.
The preparation is developed on the basis of decoction, the extraction of active ingredients in the traditional Chinese medicine is a complex process, the active ingredients are degraded and damaged by the extraction method in the extraction process, and the extraction rate of the active ingredients is low, so that the utilization rate of the medicinal materials is low, the medicine effect is poor, and the medicine effect is limited after each administration. Therefore, a preparation with high utilization rate and high drug effect is urgently needed.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides jade screen powder micro powder and a preparation method and application thereof, which solve the problems of low utilization rate, poor drug effect and limited drug effect after taking in the prior art.
On one hand, the invention provides a preparation method of jade screen powder, which comprises the following steps:
s1, weighing raw materials: weighing the following raw materials in parts by weight: 2 parts of astragalus, 2 parts of bighead atractylodes rhizome and 1 part of divaricate saposhnikovia root;
s2, drying: mixing the raw materials in the step S1, and drying;
s3, primary sieving: crushing the dried raw materials, and sieving for the first time;
s4, secondary sieving: and (4) crushing the raw materials after primary sieving for the second time, and sieving for the second time to obtain the jade screen powder micropowder.
Further, in step S2, the drying temperature is 60 ℃ and the drying time is 3h.
Further, in step S3, the pulverizing time is 20S, and the mesh size of one-time sieving is 60 meshes.
Further, in step S4, the pulverizing time is 2min, and the mesh number of the secondary sieving is 100 meshes.
Further, step S2 is preceded by a step of preprocessing: the pretreatment comprises cleaning and airing the raw materials.
Has the advantages that: in order to ensure that the jade screen powder has better quality, the raw medicinal materials are pretreated. The water used for cleaning may be one of tap water, distilled water and deionized water.
On the other hand, the invention provides the jade screen powder micro powder which is prepared by the preparation method of the jade screen powder micro powder.
Further, the particle size of the fine powder is 150 μm.
Further, the active ingredient content of miropowder includes Rui isoflavone glucoside 0.0455/g, turquoise glycoside 0.1032/g, atractylodes macrocephala lactone III 0.0309/g, light red flower bud phenol glycoside 0.0151/g, 5-O-methyl vitamin A rice alcohol glycoside 0.1143/g.
In another aspect of the invention, the invention provides an application of the jade screen powder micro powder in preparing a medicine for treating escherichia coli infection.
The technical principle of the invention is as follows: after the traditional Chinese medicine is prepared into micro powder, the curative effect is improved compared with the ordinary powder. On one hand, as the particle size of the powder is reduced, the specific surface area is increased, the contact area of the powder and the outside is increased, and the dissolution of effective substances is facilitated; on the other hand, compared with coarse powder, the traditional Chinese medicine micro powder has smaller central particle size of raw medicinal materials, and the cell wall breaking rate at the particle size is increased, thereby being beneficial to the full exposure of effective components in the medicinal materials. Therefore, after the traditional Chinese medicine is prepared into micro powder, the dissolution speed and the dissolution amount of chemical components are greatly improved.
Compared with the prior art, the invention has the following beneficial effects:
(1) The preparation method is simple, the extraction process is omitted, the preparation process is simplified, and the preparation efficiency is improved.
(2) The preparation method of the invention greatly improves the content of active ingredients and saves the cost of medicinal materials.
(2) The jade screen powder prepared by the invention is a pure traditional Chinese medicine preparation, has few auxiliary materials, small side effect, safety and reliability.
(3) The jade screen powder prepared by the invention has obvious curative effect on colibacillosis, can enhance the immunocompetence of mice, and saves the breeding cost.
Drawings
FIG. 1 is a diagram showing the effective components of the fine powder of Jade Screen in test example 1 of the present invention; wherein, note: peak 1 is cimicidin glycoside, peak 2 is calycosin glucoside, peak 3 is 5-O-methylvisammioside glycoside, peak 4 is Helimoside, and peak 5 is atractylenolide III.
FIG. 2 is a graph showing the growth of a mouse in test example 2 of the present invention.
Detailed Description
The technical solution of the present invention is further explained with reference to the drawings and the embodiments.
Example 1 preparation of fine powder of Jade Screen
a. Pretreatment: selecting clean, mildew-free, worm-eaten-free and good-appearance radix astragali, rhizoma atractylodis macrocephalae and radix sileris, washing the qualified raw material medicines with water until the color of the water is clear, and then airing or draining the raw material medicines.
b. And b, mixing the astragalus, the bighead atractylodes rhizome and the divaricate saposhnikovia root which are treated in the step a according to a weight ratio of 2.
c. B, putting the medicinal materials mixed in the step b into a constant-temperature drying oven for drying, wherein the set parameters are that the drying temperature is 60 ℃ and the drying time is 3 hours;
d. c, crushing the dried medicinal materials in the step c for 20s by using a high-speed traditional Chinese medicine crusher, and sieving by using a 60-mesh sieve to obtain traditional Chinese medicine coarse powder;
e. d, repeating the step d until all the medicinal materials are sieved or no medicinal materials can be sieved;
f. d, crushing the traditional Chinese medicine coarse powder obtained in the step d for 2min by using a traditional Chinese medicine high-speed crusher, and sieving the powder by using a 100-mesh sieve to obtain jade screen powder micro powder with the corresponding particle size of 150 mu m;
g. and f, weighing a proper amount of the jade screen micropowder obtained in the step f, preparing 1g/100mL of jade screen micropowder suspension by using distilled water as a dispersing agent, and fully stirring to uniformly disperse the jade screen micropowder particles. And transferring the sample liquid into a laser particle analyzer sample injector added with distilled water, adjusting until the light shading degree reaches 15-20%, and measuring the particle size and distribution of the powder, wherein the D90 value is lower than 150 mu m, and the powder is qualified. The set parameters of the laser particle size analyzer are as follows: the sample material is set to be medicinal powder, the refractive index of the sample material is 1.5, the absorptivity of the sample material is 0.1, the dispersion medium is water, the refractive index of the dispersion medium is 1.333, and the light shading degree is 15% -20%.
Comparative example 1 preparation of fine powder of jade Screen powder
Similar to example 1, except that the dried herb was pulverized and sieved through a 80 mesh sieve in step f.
Comparative example 2 preparation of ultra-fine powder of Yupingfeng powder
Similar to example 1, except that the Chinese medicinal coarse powder is pulverized and sieved with a 200-mesh sieve in step f.
Test example 1 detection of effective Components
The effective components of the jade screen powder are detected by high performance liquid chromatography, the results are shown in figure 1 and table 1, and the results show that the content of each effective component in example 1 is higher than that in comparative example 1, and the effective components have no significant difference from comparative example 2.
TABLE 1 effective component content of fine powder of Yupingfeng powder
| Group of | Rui isoflavone glucoside (mg/g) | Shengma Ma glycoside ([ mu ]/g) | Helaomao phenol glycoside (mg/g) | 5-O-methyl visammioside ('/g) |
| Example 1 | 0.0455 | 0.1032 | 0.0151 | 0.1143 |
| Comparative example 1 | 0.0290 | 0.0919 | 0.0063 | 0.0369 |
| Comparative example 2 | 0.0438 | 0.1001 | 0.0155 | 0.1119 |
Experimental example 2 study on in vivo antibacterial effect of fine powder of Jade Screen powder on Escherichia coli
1. The method comprises the following steps: 54 Kunming mice are male, the weight of the male mice is 20-40 g, and the male mice are randomly divided into 6 groups: blank group, model group, yupingfeng san granule finished medicine group, comparative example 1 group, example 1 group and comparative example 2 group, wherein 9 pieces of medicine are contained in each group. After adaptive feeding for 7 days, continuously performing intragastric administration for 7 days, and performing intragastric administration once a day, wherein each time is 0.173ml/20g; the blank group and the model group are filled with normal saline, finished medicine, namely the finished water solution of the gavage jade screen powder, 80-mesh micro powder extracting solution of the gavage jade screen powder in the comparative example 1, 100-mesh micro powder extracting solution of the gavage jade screen powder in the example 1 and 200-mesh micro powder extracting solution of the gavage jade screen powder in the comparative example 2. The jade screen powder micro powder extracting solution is prepared into extracting solution by adopting a heating reflux method, and the finished medicine of the jade screen powder is prepared into aqueous solution by taking water as a solvent, wherein the concentration of the four medicines is 1g/mL. On the eighth day, the blank group was injected with normal saline, the model group, yupingfeng san product medicine group, comparative example 1 group, and comparative example 2 group were injected with Escherichia coli (concentration 1 × 10) 9 CFU·mL -1 ) And 0.2 mL/piece. The mice are bled, the bacterial clearance in the blood is detected, the blood is bled after 2h, 4h and 6h respectively, sacrificed and dissected, the content of each organ and cecum is collected, and the organ index and the bacterial clearance in the middle of the blood and the excrement are calculated.
The mental state, fur, diet, excretion and death of the mice were observed during the test, and body weights were collected. After injection, pathological changes and clinical manifestations of the mice are observed, indexes such as organ indexes, blood bacteria clearance rate, excrement bacteria clearance rate and the like are measured, and the antibacterial effect is investigated.
2. As a result: in clinical manifestation, mice in each experimental group have different degrees of symptoms such as bradykinesia, deterioration of mental state and the like compared with mice in a blank group, and the mice in the gastric lavage example 1 group, the comparative example 2 group and the Yupingfeng powder finished product medicine group show good mental state, have no difference in aspects such as hair coating, drinking, ingestion, excretion and the like, have no pathological conditions such as diarrhea and the like, and have no death. In the comparative example 1, the mice had poor mental state, slow reaction, poor color of fur, bad diet, and clinical phenomena such as convulsion and diarrhea in the back of the bow and no death of the mice. All mice in the model group showed diarrhea and 2 died.
In the aspect of the growth curve of the mouse, as shown in fig. 2, the result shows that after the injection of escherichia coli, compared with the model group, the weight loss of the mouse can be reduced to a certain degree after the mouse is continuously drenched with the finished product of yupingfeng powder, the comparative example 1 and the comparative example 2. In addition, in the three micropowder samples, the weight loss of the mice is the least obvious after the escherichia coli injection in the group of example 1, and the weight loss of the mice is the most obvious after the escherichia coli injection in the group of comparative example 1. The jade screen powder is used as a classic formula for strengthening the body resistance and consolidating the constitution in the field of traditional Chinese medicine, has a certain health-care effect of strengthening the body and can reduce the weight loss caused by escherichia coli.
After the injection of escherichia coli, the pathological changes and clinical symptoms of mice in the group of example 1, the Yupingfeng powder finished drug group, the group of comparative example 1 and the group of comparative example 2 are all relieved. For organ index, see table 2. The results show that the injection of the Escherichia coli causes the enlargement of all organs of the mice to a certain degree, and the perfusion of the group 1, the group 1 and the group 2 can effectively relieve the edema symptom and improve the quality of spleen immune organs. The extraction solutions of the jade screen powder of the groups of example 1, comparative example 1 and comparative example 2 can slightly stimulate the development of immune organs of mice, can promote the development of the immune organs and improve the immunity of organisms, and the group of example 1 has the best effect and is superior to the finished medicine of the jade screen powder.
TABLE 2 mouse organ index table
| Group of | Liver index | Spleen index | Index of lung | Renal index |
| Blank group | 50.18±3.35 | 4.35±1.45 | 6.79±1.73 | 14.15±4.34 |
| Model set | 48.97±4.32 | 4.47±1.72 | 6.78±1.21 | 14.72±1.35# |
| Example 1 | 51.21±4.57 | 4.26±1.34 | 7.43±2.14 | 13.67±3.26* |
| Comparative example 1 | 48.75±4.54 | 3.61±0.74* | 6.98±0.98 | 14.07±3.09* |
| Comparative example 2 | 55.35±8.23 | 3.89±0.79 | 13.05±4.20** | 15.19±1.49 |
| Finished medicine group | 51.63±7.03 | 3.77±1.62 | 6.89±1.07 | 14.80±2.91 |
* Represents significant difference compared with the model group (P < 0.05), # represents significant difference compared with the model group (P < 0.01), # represents significant difference compared with the blank group (P < 0.05)
In the aspect of blood bacteria clearance, see table 3, the results show that the mice in the group of gavage example 1, the group of comparative example 1 and the group of comparative example 2 can effectively reduce the quantity of bacteria in blood, the effect of the finished drug group of Yupingfeng san is better before 4h, and the effect of each micro powder group is better than that of the finished drug group of Yupingfeng san at 6 h. The group of example 1 was more effective than the group of comparative example 1 and the group of comparative example 2. The jade screen powder and the micro powder can achieve the long-term protection effect on the organism by enhancing the immunity of the organism.
TABLE 3 mouse blood bacteria clearance
In the aspect of fecal bacteria clearance, see table 4, the results show that the mice of the gavage example 1 group, the comparative example 1 group and the comparative example 2 group can effectively reduce the number of bacteria in the feces, and the effect of the example 1 group is better than that of the comparative example 1 group and the comparative example 2 group.
TABLE 4 bacterial clearance of mouse feces
In general, after the extract liquid of the group 1 is fed, the growth performance of the mice is improved, the development of immune organs of livers and spleens tends to be promoted, the pathological changes and clinical symptoms of the mice after virus attack can be relieved, and the bacteria removal is accelerated. The effect of the group of comparative example 1 is significantly weaker than that of the group of example 1, which is probably because the micro powder of the group of comparative example 1 has a larger crushed particle size in the preparation process, so that the specific surface area of the powder particles is smaller, and the effective components in the raw materials are not easy to dissolve out, thereby affecting the effect. The group of comparative example 2 also had slightly less effect than example 1. The effect of the micropowder is better than that of the finished granule.
Test example 3 measurement of elution amount of active substance in simulated human body Environment
The results of high performance liquid chromatography measurement of example 1, comparative example 1 and comparative example 2 in an environment of artificial gastric juice, rotation speed of 75r/min and temperature of 37 earth of 0.5 ℃ for 4h after digestion are shown in table 5, and the results show that the content of each active ingredient in example 1 is higher than that in comparative example 1 and comparative example 2, and show that the active ingredient in example 1 is eluted in the human body environment in the highest amount compared with that in comparative example 1 and comparative example 2, and the elution amount in comparative example 2 is lower than that in example 1 because the active substance is eluted more easily as the particle size of the powder particles is reduced, the surface area is increased, contact with the external solute is increased, the adsorption capacity is also increased, the elution of the active substance is hindered, and the antibacterial effect is lower than that in example 1.
TABLE 5 simulation of elution of active substances in human body environment
In conclusion, the jade screen powder micro powder prepared by the invention has a certain antibacterial effect on escherichia coli in animals, has small toxic and side effects, and has a better antibacterial effect than that of comparative examples 1-2. The effect of the micro powder is better than that of the finished product of granules among different formulations.
Finally, although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that various changes and modifications may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.
Claims (9)
1. A preparation method of jade screen powder is characterized by comprising the following steps:
s1, weighing raw materials: weighing the following raw materials in parts by weight: 2 parts of astragalus membranaceus, 2 parts of bighead atractylodes rhizome and 1 part of divaricate saposhnikovia root;
s2, drying: mixing the raw materials in the step S1, and drying;
s3, primary sieving: pulverizing the dried raw materials, and sieving for one time;
s4, secondary sieving: and (4) crushing the raw materials after primary sieving for the second time, and sieving for the second time to obtain the jade screen powder micropowder.
2. The method for preparing the jade screen micropowder of claim 1, which is characterized by comprising the following steps: in the step S2, the drying temperature is 60 ℃, and the drying time is 3h.
3. The method for preparing the jade screen micropowder of claim 1, which is characterized by comprising the following steps: in step S3, the crushing time is 20S, and the mesh number of one-time sieving is 60 meshes.
4. The method for preparing the jade screen micropowder of claim 1, which is characterized by comprising the following steps: in step S4, the crushing time is 2min, and the mesh number of the secondary sieving is 100 meshes.
5. The method for preparing the jade screen micropowder of claim 1, which is characterized by comprising the following steps: the method also comprises the following preprocessing step before the step S2: the pretreatment comprises cleaning and airing the raw materials.
6. A jade screen powder is characterized in that: obtained by the production method according to any one of claims 1 to 5.
7. The jade screen micropowder of claim 6, wherein: the particle size of the micro powder is 150 mu m.
8. The jade screen micropowder of claim 6, wherein: the active ingredient content of miropowder includes that Rui isoflavone glucoside 0.0455/g, turquoise glycoside 0.1032 mg/g, atractylenolide III 0.0309 mg/g, sec-hamamethol glycoside 0.0151 mg/g, 5-O-methyl vitamin A rice alcohol glycoside 0.1143 mg/g.
9. The use of the jade screen powder of any one of claims 6-8 in the preparation of a medicament for treating escherichia coli infection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211156884.0A CN115475189A (en) | 2022-09-22 | 2022-09-22 | Jade screen powder micro powder and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211156884.0A CN115475189A (en) | 2022-09-22 | 2022-09-22 | Jade screen powder micro powder and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115475189A true CN115475189A (en) | 2022-12-16 |
Family
ID=84394836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211156884.0A Pending CN115475189A (en) | 2022-09-22 | 2022-09-22 | Jade screen powder micro powder and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115475189A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101579364A (en) * | 2008-05-14 | 2009-11-18 | 北京和润创新医药科技发展有限公司 | Pharmaceutical composition and preparation method thereof |
-
2022
- 2022-09-22 CN CN202211156884.0A patent/CN115475189A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101579364A (en) * | 2008-05-14 | 2009-11-18 | 北京和润创新医药科技发展有限公司 | Pharmaceutical composition and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 王健炜 等: "玉屏风散影响上呼吸道甲型链球菌生长的实验研究", 《云南中医学院学报》, vol. 31, no. 2, pages 20 - 22 * |
| 路立峰 等: "玉屏风方制剂质量控制的研究进展", 《中华中医药学刊》, vol. 38, no. 11, pages 62 - 65 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1723981A (en) | Novel use of extractive of Momordica grosvenori as adjuvant drug for preparing medicine | |
| CN102114102B (en) | Traditional Chinese medicine extract mixed preparation and application thereof | |
| CN103536761A (en) | Traditional Chinese medicine preparation for treating gout and preparation method of traditional Chinese medicine preparation | |
| CN101327302B (en) | Chuan Xiong Tea soft capsule and method for preparing the same | |
| CN105535448A (en) | Traditional Chinese medicine composition for treating child myasthenia gravis | |
| Chen et al. | Cassiae Semen: A comprehensive review of botany, traditional use, phytochemistry, pharmacology, toxicity, and quality control | |
| CN101940642B (en) | Chinese medicinal composition and application thereof | |
| CN109045229A (en) | The Chinese medicine composition and preparation method thereof for treating urarthritis | |
| CN1785249B (en) | Novel use of medicine composition containing red-rooted salvia | |
| CN106491834A (en) | A kind of veterinary Chinese medicinal composition and its preparation method and application of granule | |
| CN115475189A (en) | Jade screen powder micro powder and preparation method and application thereof | |
| CN100998782B (en) | Traditional Chinese medicine oral liquid for treating gastrointestinal disease and its preparing method | |
| CN105801639A (en) | Method for extracting stevioside from stevia rebaudiana and stevioside product | |
| CN105640970B (en) | Effective part of ginseng stem and leaf and preparation method and application thereof | |
| CN100400081C (en) | Medicine for treating diabetes and production method thereof | |
| CN108658923A (en) | A method of extracting purple sweet potato cyanidin with acidic oxidized electric potential water | |
| CN103690768A (en) | Creeping liriope-figwort-milkvetch root soft capsules and preparation method thereof | |
| CN1712060A (en) | Preparation of Chinese medicinal mixture for treating gynecologic menstrual disease | |
| CN107648397B (en) | Traditional Chinese medicine composition for treating liver-kidney yin deficiency and preparation method and application thereof | |
| CN1537545A (en) | Sugar-free type blood-fat-lowering granule, and its prepn. method | |
| CN104547803A (en) | Traditional Chinese medicine composition for postpartum fevers of women for clearing away heat and toxic materials | |
| CN1124153A (en) | Medicine for recovery and replenishing liver and its preparing method | |
| CN104189492A (en) | Traditional Chinese medicine preparation with hypoglycemic effect | |
| CN110025704B (en) | Compound Chinese herbal medicine preparation for treating piglet diarrhea and preparation method thereof | |
| CN105748996A (en) | Traditional Chinese medicine composition for decreasing blood sugar and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20221216 |